Spondyloarthritis & psoriatic arthritis
Psoriatic arthritis risk in psoriasis patients prescribed acitretin versus disease-modifying antirheumatic drugs: a nationwide cohort study
Main finding · PsA developmentResult — go to the resultHazard ratio 0.83 95% CI 0.65–1.05Authors' conclusion
Compared with DMARDs, acitretin was not associated with increased PsA risk in PsO patients.
Study context
- Population
- Adult psoriasis (PsO) patients without PsA, Taiwan's National Health Insurance Research Database, 1997–20131,948 per cohort
- Participants
- 1,948 vs 1,948
- Exposure
- Acitretin vs DMARDs in PsO patients
- Acitretinn = 1,948
- DMARDsn = 1,948reference
- Outcome
- Risk of PsA
Methodological detailsnationwide, Cox regression adjusted for demographic and clinical covariates
- Nationwide
- Cox regression adjusted for demographic and clinical covariates
Main finding
PsA development
Hazard ratio
0.83
95% CI 0.65–1.05
Acitretinvs DMARDs
HR 0.83 (95% CI 0.65–1.05)
As reported in the abstract
Observational data: associations, not effects.
Further findings
5-year cumulative incidence of PsA
P = 0.005
5-year cumulative incidence of PsA, without NSAIDs (subgroup)
P = 0.106
5-year cumulative incidence of PsA
- More pronounced difference in the subpopulation receiving NSAIDs
Other independent risk factors for PsA
- Female sex and NSAIDs treatment
Original publication
Psoriatic arthritis risk in psoriasis patients prescribed acitretin versus disease-modifying antirheumatic drugs: a nationwide cohort study. Rheumatology (Oxford). Published 1 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →